GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO’s Evan Seigerman

Evan Seigerman, BMO senior analyst, joins ‘Closing Bell Overtime’ to talk today’s Capitol Hill hearing with Novo Nordisk’s CEO and the demand for weight-loss drugs.